Is ALNYLAM PHARMACEUTICALS, INC. (ALNY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.0% / 30% | 6.8% / 30% | 1.8% / 30% | 3.0% / 5% | ✓ HALAL |
| DJIM | 3.0% / 33% | 6.8% / 33% | 1.8% / 33% | 3.0% / 5% | ✓ HALAL |
| MSCI | 25.7% / 33% | 58.6% / 33% | 15.7% / 33% | 3.0% / 5% | ✗ NOT HALAL |
| S&P | 3.0% / 33% | 6.8% / 33% | 1.8% / 33% | 3.0% / 5% | ✓ HALAL |
| FTSE | 25.7% / 33% | 58.6% / 33% | 15.7% / 50% | 3.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 81.6% | |
| Operating Margin | 12.0% | |
| Net Margin | 8.4% | |
| Return on Equity (ROE) | 73.3% | |
| Return on Assets (ROA) | 6.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $524M |
| Free Cash Flow | $465M |
| Total Debt | $1.3B |
| Debt-to-Equity | 376.2 |
| Current Ratio | 2.8 |
| Total Assets | $5.0B |
Price & Trading
| Last Close | $328.16 |
| 50-Day MA | $331.57 |
| 200-Day MA | $392.87 |
| Avg Volume | 1.3M |
| Beta | 0.4 |
|
52-Week Range
$205.87
| |
About ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Purification Calculator
As a halal stock with 3.00% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ALNYLAM PHARMACEUTICALS, INC. (ALNY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ALNYLAM PHARMACEUTICALS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ALNYLAM PHARMACEUTICALS, INC.'s debt ratio?
ALNYLAM PHARMACEUTICALS, INC.'s debt ratio is 3.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 25.7%.
Does ALNYLAM PHARMACEUTICALS, INC. require dividend purification?
Yes, ALNYLAM PHARMACEUTICALS, INC. has an impermissible income ratio of 3.00%, which means 3.00% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are ALNYLAM PHARMACEUTICALS, INC.'s key financial metrics?
ALNYLAM PHARMACEUTICALS, INC. has a market capitalization of $42.1B, trailing P/E ratio of 136.8, and revenue of $3.7B. The company maintains a gross margin of 81.6% and a net margin of 8.4%. Return on equity stands at 73.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.